The end of Novo Nordisk’s supply problems could bring new headaches for the rest of the pharmaceutical industry, which now ...

AS GLP-1 AGONISTS soar in popularity—about 12 percent of the U.S. population has tried one, most often Ozempic or Wegovy ...

Part of the joy of the season may be gone — or feel different — for people who are taking popular weight-loss drugs and can't ...

The Danish Medicines Agency had been watching reports of a rare eye disease in patients who took Novo’s GLP-1 drug but until ...

Investors' focus could, however, shift back onto the possible market impacts of GLP-1 agonists in 2025, particularly as a result of a major expansion of current supplies after Novo Nordisk was given a ...

Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the ...

It's been six months since I accidentally poisoned myself with a weight-loss jab I shouldn't have taken. But while the memory ...

STOCKHOLM/LONDON (Reuters) -Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in ...

The $16.5 billion take-private deal can now be completed, and along with it Novo Nordisk’s related acquisition of three ...

Copenhagen: Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight loss treatments Ozempic and Wegovy, said Monday it was investing ...

Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, said Monday it was ...

Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, which have gained ...